Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Stefan Hantel"'
Autor:
Stefan Kaspers, Stuart J. Pocock, Stefan D. Anker, Michaela Mattheus, Silvio E. Inzucchi, Søren S Lund, Maximilian von Eynatten, Christoph Wanner, Jyothis T. George, Waheed Jamal, Stefan Hantel, Bernard Zinman, Odd Erik Johansen, David Fitchett, Ulrich Elsasser, Darren K. McGuire
Publikováno v:
The Lancet Diabetes & Endocrinology. 8:949-959
Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in t
Autor:
Christoph Wanner, David C. Wheeler, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Jyothis T. George, Adeera Levin, Vlado Perkovic
Publikováno v:
Clin J Am Soc Nephrol
Background and objectives In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG Outcome), empagliflozin, in addition to standard of care, significantly reduced risk of cardiovascular death by 38%, hosp
Publikováno v:
Diabetologia
Aims/hypothesis In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 d
Autor:
Leo Seman, Hans-Juergen Woerle, Julio Rosenstock, Thomas Hach, Stefan Hantel, Sabine Pinnetti, Ante Jelaska
Publikováno v:
Diabetes, Obesity and Metabolism. 15:1154-1160
Aims To evaluate the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin added to metformin for 12 weeks in patients with type 2 diabetes. Methods This dose-ranging, double-blind, placebo-controlled trial randomized 495 part
Autor:
Sabine Pinnetti, E. Seewaldt-Becker, Eleuterio Ferrannini, Leo Seman, Hans-Juergen Woerle, Stefan Hantel
Aim This Phase IIb, randomized, double-blind, placebo-controlled trial evaluated the efficacy, safety, tolerability and pharmacokinetics of empagliflozin in patients with type 2 diabetes. Methods Four hundred and eight patients (treatment-naive or af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::628355accc5d6f217b55b6412504af91
http://hdl.handle.net/11568/506135
http://hdl.handle.net/11568/506135
Autor:
E. Seewaldt-Becker, Hans-Juergen Woerle, Stefan Hantel, Sreeraj Macha, Leo Seman, Sabine Pinnetti, Tim Heise
Publikováno v:
Diabetes, obesitymetabolism. 15(7)
Aim To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of empagliflozin in patients with type 2 diabetes following oral administration of 10, 25 or 100 mg doses once daily over 28 days. Methods A total of 78 patients were